Abstract: Conductive traces may be conformally wrapped around the side of a display panel that includes an array of display pixels. The conductive traces may electrically connect contacts on an upper surface of the display panel to corresponding contacts on a flexible printed circuit that is attached to a lower surface of the display panel. The side-wrapped conductive traces may be interposed between first and second insulating layers. The flexible printed circuit may have a multi-step interface that is electrically connected to the side-wrapped conductive traces. A system-in-package including a display driver integrated circuit may be mounted to the flexible printed circuit. The system-in-package may include a plurality of redistribution layers that electrically connect contacts on the display driver integrated circuit to contacts on the flexible printed circuit.

Abstract: Provided are macrolide compounds for the treatment of infectious diseases. The macrolides disclosed herein include 14-membered ketolides and 14-15-membered azaketolides, and may comprise modified sugars which are desosamine analogues. The disclosed macrolides may have a bicyclic structure. Also provided are pharmaceutical compositions and methods of treating infectious diseases, and in particular, disease which results from Gram negative bacteria using the disclosed macrolides. This disclosure additionally provides methods of preparing the macrolides by a strategy that enables late-stage modification of the 6?-position of the sugar moiety, thereby allowing facile access to previously difficult-to-make macrolide compounds.

Abstract: Described herein, inter alia, are Ras inhibitors and uses thereof.

Abstract: Provided are macrolide compounds for the treatment of infectious diseases. The macrolides disclosed herein include 14-membered ketolides and 14-15-membered azaketolides, and may comprise modified sugars which are desosamine analogues. The disclosed macrolides may have a bicyclic structure. Also provided are pharmaceutical compositions and methods of treating infectious diseases, and in particular, disease which results from Gram negative bacteria using the disclosed macrolides. This disclosure additionally provides methods of preparing the macrolides by a strategy that enables late-stage modification of the 6?-position of the sugar moiety, thereby allowing facile access to previously difficult-to-make macrolide compounds.

Abstract: Provided herein are methods of preparing macrolides by the coupling of an eastern and western half, followed by macrocyclization, to provide macrolides, including both known and novel macrolides. Intermediates in the synthesis of macrolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using the inventive macrolides are also provided. A general diastereoselective aldol methodology used in the synthesis of the western half is further provided.

Abstract: A device including a bottom electrode on a substrate and a top electrode on a substrate separated by a fixed distance from each other. Semi-insulator layers with proper electrical conductivity are attached to the bottom and top electrodes. Disposed between the substrates is a flexible S-shaped polymer stack having electrode layers with one end of the stack attached to the top substrate and the other end in contact with the bottom substrate. When a voltage is applied between the stack and the electrode layer on the bottom substrate, the stack is induced by electrostatic force to deflect in a rolling wave-like motion. While the voltage applied between the stack and bottom electrode is turned off, the static charges on the semi-insulator layer can move away quickly due to the proper electrical conductivity of the semi-insulator layer.

Abstract: Provided, inter alia, are methods and compositions for treating cancer.

Abstract: Provided herein are methods of preparing new 14-membered ketolides via coupling of an eastern and western half moiety, followed by macrocyclization, and optional functionalization. Intermediates in the synthesis of these ketolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using these ketolides are also provided.

Abstract: Provided are 13-membered macrolides for the treatment of infectious diseases. The 13-membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13-membered macrolides, pharmaceutical compositions comprising the 13-membered macrolides, and methods of treating infectious diseases, and in particular, disease resulting from Gram negative bacteria using the disclosed macrolides.

Abstract: Described herein, inter alia, are immunophilin binding compounds and methods of heating CNS diseases, including co-administering outside the CNS of a subject an anti-CNS disease drug and a compound described herein.

Abstract: Disclosed herein is a system for evaluating a user during a physical cannulation simulation. The system includes a physical cannulation simulator and one or more sensors configured to measure data during the physical cannulation simulation by the user using the physical cannulation simulator. The system further includes one or more processors configured to receive the data measured by each of the one or more sensors and calculate metrics using the data. The one or more processors are further configured to apply a model to the metrics to determine a composite simulation success score and compare the composite simulation success score to a threshold score. In response to comparing the composite simulation success score to the threshold score, the one or more processors are configured to output an indication of one or more of an absolute performance or a relative performance for the first user during the physical cannulation simulation.

Abstract: Provided herein are macrolide compounds of Formula (I) and (I-N) for the treatment of infectious diseases and inflammatory conditions. The 14-membered ketolides and 14-, 15-, and 16-membered azaketolides described herein comprise modified sugars which are desosamine or mycaminose analogs. Pharmaceutical compositions and methods of treating infection diseases and inflammatory conditions using the inventive macrolides are also provided. This disclosure additionally provides methods of preparing the macrolides by the coupling of an eastern and western half.

Abstract: Provided herein are methods of preparing macrolides by the coupling of an eastern and western half, followed by macrocyclization, to provide macrolides, including both known and novel macrolides. Intermediates in the synthesis of macrolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using the inventive macrolides are also provided. A general diastereoselective aldol methodology used in the synthesis of the western half is further provided.

Abstract: Provided herein are methods of preparing new 14-membered ketolides via coupling of an eastern and western half moiety, followed by macrocyclization, and optional functionalization. Intermediates in the synthesis of these ketolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using these ketolides are also provided.

Abstract: Provided are macrolide compounds for the treatment of infectious diseases. The macrolides disclosed herein include 14-membered ketolides and 14-15-membered azaketolides, and may comprise modified sugars which are desosamine analogues. The disclosed macrolides may have a bicyclic structure. Also provided are pharmaceutical compositions and methods of treating infectious diseases, and in particular, disease which results from Gram negative bacteria using the disclosed macrolides. This disclosure additionally provides methods of preparing the macrolides by a strategy that enables late-stage modification of the 6?-position of the sugar moiety, thereby allowing facile access to previously difficult-to-make macrolide compounds.

Abstract: The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and neoantigen-binding fragments. The antibodies and neoantigen binding-fragments are useful for diagnosis and treatment of cancer.

Abstract: A solid-state heat transporting device including a heat transporting element whose uniformity of contact with one or multiple surfaces is controllable so that various amounts of heat may be transported to and from the one or multiple surfaces. The heat transporting element uses the electrocaloric effect to absorb and release the heat and the uniformity of contact is controlled using an electrostatic effect which may change the shape of the heat transporting element. In one embodiment, the heat transporting element is an electrostatically actuated P(VDF-TrFE-CFE) polymer stack achieving a high specific cooling power of 2.8 W/g and a COP of 13 (the highest reported coefficient of performance to date) when used as a cooling device.

Abstract: Disclosed herein, inter alia, are immunophilin binding compounds and methods of using the same.

Abstract: The present invention provides a method for whole-process trace leaving of video manuscript gathering, editing, and check, including: extracting a key frame from video clipping information, generating histogram data by using the key frame, and obtaining video modification information based on the histogram data; and on-chaining, by using timestamps as blockchain nodes, the video modification information completed at different time points to form a trace chain arranged according to the timestamp, to implement whole-process trace leaving for video clipping. The technical solutions of the present invention resolve a difficulty in whole-process trace leaving for video manuscript editing and issuing, and in addition, by using the blockchain techniques, implement tamper-proofing and security of trace information, thereby effectively improving security of gathering and editing in the media industry.

Abstract: Provided are 13-membered macrolides for the treatment of infectious diseases. The 13-membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13-membered macrolides, pharmaceutical compositions comprising the 13-membered macrolides, and methods of treating infectious diseases, and in particular, disease resulting from Gram negative bacteria using the disclosed macrolides.